...
首页> 外文期刊>The Journal of Nuclear Medicine >Serotonin Transporters in the Midbrain of Parkinsona€?s Disease Patients: A Study with 123I-?2-CIT SPECT
【24h】

Serotonin Transporters in the Midbrain of Parkinsona€?s Disease Patients: A Study with 123I-?2-CIT SPECT

机译:帕金森病患者中脑的5-羟色胺转运蛋白:123I-β2-CITSPECT研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

id="p-1">In Parkinsona€?s disease (PD), both neuropathologic and biochemical studies suggest that serotonin (5-hydroxytryptamine [5-HT]) neurons are affected by the disease process. The integrity of 5-HT transporters was assessed in PD patients with SPECT using 2?2-carbomethoxy-3?2-(4-123I-iodophenyl)tropane (123I-?2-CIT), which binds with high affinity to both dopamine (DA) and 5-HT transporters. >Methods: Forty-five PD patients at relatively early stages (mean Hoehn-Yahr stage, 2.0 ?± 0.7; range, 1-3) and 7 age-matched healthy control subjects had 15 scans over a 24-h period after injection of 123I-?2-CIT using a 3-head SPECT system. In the midbrain, the 5-HT transporter parameter k3/k4 was estimated by 3 noninvasive methods: pseudoequilibrium ratio (RPE) method, area ratio (RA) method, and a modified graphic method that derives the ratio of ligand distribution volumes (RV). Striatal V3a€3, the DA transporter parameter that is equivalent to k3/k4, was measured using the images acquired at 24 h after tracer injection. All measures were derived using the cerebellum as the reference region. >Results: In control subjects, the 123I-?2-CIT activity in the midbrain reached a peak at 91 ?± 21 min after injection and then washed out at a slow rate (1.1%/h ?± 0.5%/h). The peak specific uptake in the midbrain occurred at 315 ?± 46 min. In PD patients, the temporal patterns of the midbrain and cerebellar activity were not significantly different from those in control subjects. None of midbrain RPE, RA, and RV was significantly different between control subjects and PD patients, whereas striatal V3a€3 was bilaterally reduced in all patients, being 32% lower than that of the control subjects (P = 0.002). In PD patients, none of the midbrain outcome measures was significantly correlated with either striatal V3a€3 or motor or nonmotor symptom ratings, including the Hoehn-Yahr stage and the Unified Parkinsona€?s Disease Rating Scale scores. When the studies of 7 PD patients with depression were analyzed separately, none of the midbrain outcome measures in these patients either was different significantly from control values or correlated with the Hamilton Depression Rating Scale score. >Conclusion: These results suggest that DA and 5-HT transporters are differentially affected in PD, and 5-HT transporters in the midbrain region may not be affected in relatively early stages of PD. Alternatively, 5-HT transporters in the remaining neurons may be upregulated, thus raising the midbrain 5-HT transporter density to almost normal levels.
机译:id =“ p-1”>在帕金森氏病(PD)中,神经病理学和生化研究均表明,血清素(5-羟色胺[5-HT])神经元受该疾病过程的影响。在PD患SPECT的PD患者中,使用2?2-羰甲氧基-3?2-(4- 123 I-碘苯基)托烷( 123 I-β2-CIT),与多巴胺(DA)和5-HT转运蛋白均具有高亲和力。 >方法:在相对早期阶段(平均Hoehn-Yahr阶段,2.0?±0.7;范围为1-3)的45名PD患者和7名年龄相匹配的健康对照受试者进行了24次15次扫描使用3头SPECT系统注射 123 I-?2-CIT后的-h周期。在中脑中,通过3种非侵入性方法估算了5-HT转运蛋白参数k 3 / k 4 :伪平衡比(R PE )方法,面积比(R A )方法和改进的图形方法得出配体分布体积比(R V )。纹状体V 3 a€3(等于k 3 / k 4 的DA转运蛋白参数)是使用在24示踪剂注入后h。所有测量均以小脑为参考区域得出。 >结果:在对照组中,注射后中脑中的 123 I-?2-CIT活性在91?±21 min达到峰值,然后缓慢冲洗掉。速率(1.1%/h≤±0.5%/ h)。中脑的最高比吸收发生在315±46分钟。在PD患者中,中脑和小脑活动的时间模式与对照组无明显差异。对照组和PD患者中脑R PE ,R A 和R V 均无显着差异,而纹状体V 3 a€3在所有患者中均双侧减少,比对照组降低32%( P = 0.002)。在PD患者中,中脑结局指标均未与纹状体V 3 a€3或运动或非运动症状评分(包括Hoehn-Yahr分期和帕金森病统一评分)显着相关量表分数。当分别对7例PD抑郁症患者的研究进行分析时,这些患者的中脑结局指标均与对照值无显着差异或与汉密尔顿抑郁量表评分相关。 >结论:这些结果表明DA和5-HT转运蛋白在PD中受到不同的影响,中脑区域的5-HT转运蛋白可能在PD的相对早期阶段不受影响。可选地,剩余神经元中的5-HT转运蛋白可以被上调,从而将中脑5-HT转运蛋白密度提高到几乎正常水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号